




Strategic risk signals

How life sciences
leaders stay ahead of
disputes in Australia

References and contacts

Bibliography

¹Class Action Participation Bound Up in Fiduciary Duty - Financial Recovery Technologies (2022); [Subscribe to The Australian | Newspaper home delivery, website, iPad, iPhone & Android apps](#) (2024 article published by the Australian titled 'Local class-action litigation now second only to the US')

² <https://www.flsd.uscourts.gov/sites/flsd/files/TransferOrder-20md2924.pdf>

³ In re: Zantac (Ranitidine) Products Liability Litigation, No. 20-md-2924, 2022 WL 21837212 (S.D. Fla. Dec. 6, 2022) – The court granted defendants' Daubert motions, excluding plaintiffs' expert testimony and subsequently dismissing the federal cases due to insufficient evidence of general causation.

⁴ Johnson v. Monsanto Co. | Cases | California | Westlaw

⁵ Hardeman v. Monsanto Co., No. 19-16636 (9th Cir. 2021) :: Justia

⁶ Pilliod v. Monsanto Co. :: 2021 :: California Courts of Appeal Decisions :: California Case Law :: California Law :: U.S. Law :: Justia

⁷ Managing the Roundup™ Litigation | Bayer Global

⁸ Johnson v. Monsanto Co. :: 2020 :: California Courts of Appeal Decisions :: California Case Law :: California Law :: U.S. Law :: Justia (Johnson case which discusses Monsanto/Bayer's reliance on EPA early opinion that glyphosate carcinogen causation was inconclusive) ; Managing the Roundup™ Litigation | Bayer Global (Bayer website maintaining denial that glyphosate is carcinogenic); [Glyphosate | US EPA](#) (current EPA webpage which maintains the EPA's position that glyphosate is not carcinogenic)

⁹ <https://www.abc.net.au/news/rural/2020-06-25/bayer-to-settle-roundup-lawsuits-with-16n-payout/12389978>

¹⁰ CTS-Case-Study-Talc-JJ.pdf

¹¹ Kent et al. v Johnson & Johnson (US\$18 million) and Schultz et al. v Johnson & Johnson (US\$22 million); [Talcum Powder Settlements - Verdicts & Payouts](#) (February 2026)

¹² FDA bowed to industry for decades as alarms were sounded over talc (Note the adverse tone taken against Johnson & Johnson in this Reuters article – making allegations that the FDA essentially turned a blind eye to potential asbestos in talc products.)

⁴ Johnson v. Monsanto Co. | Cases | California | Westlaw

⁵ Hardeman v. Monsanto Co., No. 19-16636 (9th Cir. 2021) :: Justia

⁶ Pilliod v. Monsanto Co. :: 2021 :: California Courts of Appeal Decisions :: California Case Law :: California Law :: U.S. Law :: Justia

⁷ Managing the Roundup™ Litigation | Bayer Global

⁸ Johnson v. Monsanto Co. :: 2020 :: California Courts of Appeal Decisions :: California Case Law :: California Law :: U.S. Law :: Justia (Johnson case which discusses Monsanto/Bayer's reliance on EPA early opinion that glyphosate carcinogen causation was inconclusive) ; Managing the Roundup™ Litigation | Bayer Global (Bayer website maintaining denial that glyphosate is carcinogenic); [Glyphosate | US EPA](#) (current EPA webpage which maintains the EPA's position that glyphosate is not carcinogenic)

⁹ <https://www.abc.net.au/news/rural/2020-06-25/bayer-to-settle-roundup-lawsuits-with-16n-payout/12389978>

¹⁰ CTS-Case-Study-Talc-JJ.pdf

¹¹ Kent et al. v Johnson & Johnson (US\$18 million) and Schultz et al. v Johnson & Johnson (US\$22 million); [Talcum Powder Settlements - Verdicts & Payouts](#) (February 2026)

¹² FDA bowed to industry for decades as alarms were sounded over talc (Note the adverse tone taken against Johnson & Johnson in this Reuters article – making allegations that the FDA essentially turned a blind eye to potential asbestos in talc products.)

¹³ Failures to Warn Supporting Products Liability Legal Claims | Products Liability Law Center | Justia ; [070011413skadden.pdf](#) (Skadden Arps article discussing the elements of making out a claim for failure to warn.)

¹⁴ Johnson & Johnson hit with class action over 'carcinogenic' baby powder | Lawyerty

¹⁵ Product Liability Pelvic Mesh: Complications, Lawsuits, & Settlements | Chicago Personal Injury Attorney | Thomas Plouff

¹⁶ Transvaginal Mesh Timeline | Boston Product Liability Lawyers

¹⁷ In re: American Medical Systems, Inc. Pelvic Repair System Products Liability Litigation, MDL No. 2325 (S.D. W. Va.).

¹⁸ In re: Ethicon, Inc. Pelvic Repair Systems Products Liability Litigation, MDL No. 2327 (S.D. W. Va.).

¹⁹ In re: Boston Scientific Corp. Pelvic Repair System Products Liability Litigation, MDL No. 2326 (S.D. W. Va.).

²⁰ Transvaginal Mesh Settlements & Verdicts: February 2026

²¹ Transvaginal Mesh Settlements & Verdicts: February 2026; J&J loses challenge to \$302 million judgment over pelvic mesh marketing | Reuters

²² Transvaginal Mesh Settlements & Verdicts: February 2026

²³ 300 Million Mesh Class Action Settlement Approved | Shine Lawyers

²⁴ Maddocks | Settlement approval for pelvic mesh class action against...

²⁵ MDL No. 3:11-md-02244-K, N.D. Tex

²⁶ Hip Replacement Lawsuit Updates & Settlements (February 2026); IN RE: DEPUY ORTHOPAEDICS (2018) | FindLaw

²⁷ \$502 Million Dollar Verdict Against Johnson & Johnson In DePuy Pinnacle Hip Implant MDL

²⁸ Hip Replacement Lawsuits | Verdicts and Settlements

²⁹ Microsoft Word - 469482_2.DOC (Statement of claim – Tammy Maree Stanford v DePuy International Limited & Anor); DePuy ASR hip implants class action | Maurice Blackburn

³⁰ Karpik v Carnival Plc [2023] HCA 39

³¹ Kathy Even, et al. v. Alcon Laboratories Inc., et al., Case No. 1:25-cv-00574, in the U.S. District Court for the District of Colorado

³² Diane Dyess v. Novo Nordisk Inc., Case No. 2:25-cv-00546, in the U.S. District Court for the Eastern District of Pennsylvania

³³ Stewart, et al. v. Aeropres Corp., et al., Case No. 1:23-cv-13207, in the U.S. District Court for the Northern District of Illinois

³⁴ Tepezza Lawsuit: Hearing Loss Claims & Lawsuit Updates

³⁵ NEC Baby Formula Lawsuit | Latest Verdicts and Settlement

³⁶ <https://www.fedcourt.gov.au/law-and-practice/practice-documents/practice-notes/gpn-undr>

³⁷ Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth [2018] FCA 1556

³⁸ Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth [2018] FCA 1556

³⁹ <https://www.fedcourt.gov.au/law-and-practice/practice-documents/practice-notes/cpn-1>

⁴⁰ <https://www.fedcourt.gov.au/law-and-practice/practice-documents/practice-notes/ip-1>

⁴¹ <https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-letters>

⁴² <https://www.tga.gov.au/news/media-releases/new-transparency-measures-prescription-medicines>

⁴³ www.tga.gov.au/sites/default/files/prescription-medicines-transparency-measures.pdf

⁴⁴ An organisation means: (a) an individual; (b) a body corporate; (c) a partnership; (d) any other unincorporated associated; or (e) a trust; that is not a small business operator, a registered political party, an agency, a State or Territory authority or a prescribed instrumentality of a State or Territory (Privacy Act, s 6C).

⁴⁵ A health service is defined as: An activity performed in relation to an individual is a health service if the activity is intended or claimed (expressly or otherwise) by the individual or the person performing it: (a) to assess, maintain or improve the individual's health; (b) where the individual's health cannot be maintained or improved – to manage the individual's health; (c) to diagnose the individual's illness, disability or injury; (d) to treat the individual's illness, disability or injury or suspected illness, disability or injury; or (e) to record the individual's health for the purposes of assessing, maintaining, improving or managing the individual's health (Privacy Act, s 6FB).

⁴⁶ Privacy Act, Sch 1.

⁴⁷ Privacy Act, s 6.

⁴⁸ Privacy Act, s 6.

⁴⁹ Privacy Act, s 6FA.

⁵⁰ Health Records and Information Privacy Act 2002 (NSW), Health Records Act 2001 (Vic) and Health Records (Privacy and Access) Act 1997 (ACT).

⁵¹ Facebook Inc v Australian Information Commissioner [2022] FCAFC 9.

⁵² Gebo Investments (Labuan) Ltd v Signatory Investments Pty Ltd [2005] NSWSC 544, [33].

⁵³ Australian Securities and Investments Commission v ActiveSuper Pty Ltd (No 1) [2012] FCA 1519 at [47].

⁵⁴ OAIC, Australian Privacy Principles guidelines – Chapter B: Key concepts, see here: <http://www.oaic.gov.au/privacy/australian-privacy-principles/australian-privacy-principles-guidelines/chapter-b-key-concepts>.

⁵⁵ OAIC Notifiable Data Breach statistics dashboard (accessed 17 February 2026)

⁵⁶ Health Records and Information Privacy Act 2002 (NSW), Health Records Act 2001 (Vic) and Health Records (Privacy and Access) Act 1997 (ACT).

⁵⁷ OAIC, Australian Privacy Principles guidelines – Chapter 2: APP 2 Anonymity and pseudonymity, see here: <http://www.oaic.gov.au/privacy/australian-privacy-principles/australian-privacy-principles-guidelines/chapter-2-app-2-anonymity-and-pseudonymity>.

⁵⁸ National Health and Medical Research Council, Guidelines approach under section 95A of the Privacy Act 1988, see here: <http://www.nhmrc.gov.au/about-us/publications/guidelines-approved-under-section-95a-privacy-act-1988>.

⁵⁹ <https://www.cyber.gov.au/business-government/asds-cyber-security-frameworks/essential-eight>

⁶⁰ Thaler v Commissioner of Patents [2021] FCA 879

⁶¹ Commissioner of Patents v Thaler [2022] FCAFC 62

⁶² Second Request for Reconsideration for Refusal to Register Théâtre D'opéra Spatial (Copyright Review Board, Sept. 5, 2023)

⁶³ Li v. Liu (Beijing Internet Court, Nov. 27, 2023)

⁶⁴ CA's SB 53, EU AI Act are both governance frameworks, but the similarities end there | IAPP

⁶⁵ <https://www.minterellison.com/articles/australia-introduces-a-national-ai-plan-four-things-leaders-need-to-know>

⁶⁶ Final report – Review of AI and the Australian Consumer Law | Treasury.gov.au

⁶⁷ Work Health and Safety Amendment (Digital Work Systems) Act 2026 (NSW)

⁶⁸ Washington Supreme Court Extends Medical-Device Manufacturers' Duty to Warn - Washington Legal Foundation

⁶⁹ Taylor v. Intuitive Surgical, Inc., 389 P.3d 517, 528 (2017)

⁷⁰ <https://www.supremecourt.vic.gov.au/sites/default/files/2024-08/Notice%20of%20Proposed%20Settlement.pdf>

⁷¹ Merck & Co, Inc, et al. v. ACE American Insurance Company, et al. No. UNN-L-2682-18

⁷² EU Medical Device Regulation (MDR 2017/745), Article 10(16)

Key contacts



Simone Mitchell
Life Sciences Sector Lead
M +61 407 234 079
Simone.Mitchell@minterellison.com



James Hutton
Health Industry Lead
M +61 416 197 158
James.Hutton@minterellison.com



David Taylor
Partner
M +61 423 182 320
E David.Taylor@minterellison.com



Jonathan Kelp
Partner
M +61 408 669 914
E Jonathan.Kelp@minterellison.com



Sonja Read
Partner
M +61 411 276 772
E Sonja.Read@minterellison.com



Zeina Milicevic
Partner
M +61 401 181 568
E Zeina.Milicevic@minterellison.com



Chelsea Gordon
AI Lead – Legal
M +61 413 804 145
E Chelsea.Gordon@minterellison.com



Kemsley Brennan
Partner
M +61 402 974 557
E Kemsley.Brennan@minterellison.com

About MinterEllison

MinterEllison is Australia's leading independent law firm enhanced by specialist consulting.

Our dedicated, full-service, multidisciplinary life sciences team advise across the life sciences product and business lifecycle – from concept to commercialisation, and beyond.

This report was prepared with contributions from Jaimie Wolbers, Rebecca Pereira, Jacky Wong, Jasper Choi, Laura Skazlic, Maria Rychkova, Fiona Chui, Mikah Pajaczkowska-Russell, Meaghan Philp, Adam Karras and Sophie Whalley.

DETECT



PROTECT

RESPOND

The information given in this publication is believed to be accurate at the date of publication. This information may have subsequently changed or have been superseded and should not be relied upon to be accurate or suitable after this date. This publication offers a general overview of its subject matter. It does not necessarily address every aspect of its subject and we disclaim all liability to the fullest extent permitted by law. It is not intended to be, and should not be, used to replace specific advice relating to individual situations and we do not offer, and this should not be seen as, legal, accounting or tax advice. If you intend to take any action or make any decision on the basis of the content of this publication you should first seek specific advice from an appropriate professional. Some of the information in this publication may be compiled from third party sources we consider to be reliable, however we do not guarantee and are not responsible for the accuracy of such.